All News
New Treatments for Systemic Sclerosis
EurekAlert!
Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
Read Article
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Read Article
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Read Article
"Don't You Know Who I am?" (5.17.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
Read Article
New Treatments for Systemic Sclerosis
aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z
Dr. John Cush RheumNow ( View Tweet)
#Scleroderma updated #EULAR2024
#recommendations @eular_org
SKIN
Are they good enough?
Great work by task force @EUSTAR_org
Do we alter initial Rx if v high mRSS?
Ex #MMF not much improvement on skin vs #RTX #Cyclo
Or combo Rx?
We need to improve #SoC
?CAR-T ? RCT
@RheumNow https://t.co/WhEzDdjVeu
Janet Pope Janetbirdope ( View Tweet)
#Scleroderma updated #EULAR2024
#recommendations @eular_org
Are they good enough?
Great work by task force @EUSTAR_org
#PAH my thoughts
Where does #sotaracept in #PAH fit in
Not mentioned
?#selexipag before #epoprostenol
For sure there is country variant
@RheumNow https://t.co/3dJ6eusSkU
Links:
Janet Pope Janetbirdope ( View Tweet)
Agree!
Liz Volkmann said it straight
Unsustainable RCTs in ILD trials in #scleroderma
Why
Can’t recruit
~same pool of early #dcSSc design RCT
UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr
🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM
Janet Pope Janetbirdope ( View Tweet)
#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating & diarrhoea) in scleroderma. How about impact on faecal incontinence symptoms? This improved throughout 20wks. Could be due improved stool consistency @RheumNow https://t.co/1t7d3M5S4Z
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Links:
Janet Pope Janetbirdope ( View Tweet)
Review of the Scleroderma spectrum disorders (full-read) https://t.co/Z7cUrVeGRR https://t.co/VkYag0uZnX https://t.co/QK6bfcYBoF
Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis sine scleroderma in children is more aggressive than in adults. 18 juvenile vs 38 adults - ssJSSc more female (39% vs 89%), more digital pitting scars/ulcers (35 vs 10.5%), Pulm (50 vs 24) & CV (50 vs 3%); w/ more deaths https://t.co/l4f5bH1IX1 https://t.co/viQcD3tN9V
Dr. John Cush RheumNow ( View Tweet)
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort
https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt
Links:
Dr. John Cush RheumNow ( View Tweet)
Who is confused about what to do for #GI symptoms in #scleroderma? @TimKanieckiMD does a masterful breakdown of gut involvement for @jhrheumatology rounds. You can read further in: https://t.co/xw6EElGIWl
@ZsuzsannaM55365 would be proud!
#MentoredResearchProjects
#dysmotility https://t.co/yLVD7Vo1SJ
Links:
Johns Hopkins Rheumatology Fellows JHRheumFellows ( View Tweet)
IL-1 recept accessory protein (IL1RAP) shown to block mediators (IL-1, IL33, IL36) that may drive systemic sclerosis. In vitro, IL1RAP inhibited fibroblasts and endothelial cells; in mouse models of SSc anti-IL1RAP decr dermal & pulmonary fibrosis. https://t.co/6YE02P4rjR https://t.co/mzw7t88Jzl
Dr. John Cush RheumNow ( View Tweet)
Epigenetics and Autoimmune Skin Disease
The central dogma proposed that genetic information predominantly transfers from DNA to RNA during gene expression to make a functional product protein.
https://t.co/VgQE2yYYmq https://t.co/fAWBifCyWv
Dr. John Cush RheumNow ( View Tweet)
Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/Vo5jIHBrPj https://t.co/TXvFypbZdw
Dr. John Cush RheumNow ( View Tweet)
